May 17-19, 2022
Delivered as a Hybrid EventBoston, MADAY 3 ✦ VIRTUAL ✦ Thu, Dec 9keyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 - EDT
search
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 - EDT
search
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 10:00am - 10:15am15 mins
Day 1 Kick-Off
- Tom Croce - Vice President, Patient Advocacy, bluebird bio
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 10:15am - 10:45am30 mins
Navigate FDA Updates on Rare Disease Product Development
- Janet Maynard - Director, FDA/CDER/OND/ORDPURM
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 10:55am - 11:40am45 mins
Uncover Risk Disclosures for Gene Therapies
- Brigid Bondoc - Of Counsel, Morrison & Foerster
- Dr. Scott Burger - Principal, Advanced Cell & Gene Therapy
- Erik Olson - Partner, Morrison & Foerster
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 11:50am - 12:35pm45 mins
Compare Global Regulatory and Commercial Pathways for Orphan Drugs
- Martine Zimmermann - Global Head of Regulatory Affairs, Alexion Pharmaceuticals
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 12:35pm - 1:45pm70 mins
Networking Break
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 1:45pm - 2:30pm45 mins
Reverse Engineering for Drug Development in Rare Diseases
- Monica Weldon - Founder/CEO, SYNGAP1 Foundation
DAY 3 ✦ VIRTUAL ✦ Thu, Dec 9 2:30pm - 4:30pm120 mins
Tune into an Audio Replay from the Face-to-Face Programming and Engage in Virtual Networking